Under the FDA-authorized expanded access (IND 176297), urcosimod is being provided by OKYO Pharma for use in a patient with severe neuropathic corneal pain who has limited therapeutic options and no ...

LONDON and NEW YORK, Jan. 23, 2026), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseas ...

OMAHA, NE - January 21, 2026 - PRESSADVANTAGE - Kugler Vision has released a new educational article titled "SMILE vs ...

When our practice adopted the Light Adjustable Lens in 2022, we did so with a clear purpose of helping patients with corneal ...

BOSTON, MA, UNITED STATES, January 8, 2026 /EINPresswire.com/ -- EyeCool Therapeutics, a clinical-stage ophthalmic ...

In a UC Irvine office, Dorota Skowronska-Krawczyk studies a video that has changed her view of a deep-sea legend. “You see it ...

Pandorum Technologies has partnered with Nucelion Therapeutics to expand manufacturing of exosome-based therapies for ocular diseases across the Asia-Pacific region.

Some parts of our bodies bounce back from injury in fairly short order. The outer protective layer of the eye—called the ...

Henderson, NV - January 16, 2026 - PRESSADVANTAGE - Las Vegas Eye Institute announces the integration of Ray-Traced ...

He consults at Nuffield Health Leeds and Nuffield Health York. Arrange an in-person or video consultation at mrkailasmunot.co ...

Lake Oswego, OR - January 08, 2026 - PRESSADVANTAGE - At Tersigni Vision, a growing number of patients are asking ...

BridgeBio Pharma (NASDAQ:BBIO) hosted an investor webinar to outline its clinical and commercial strategy for infigratinib, ...